Page 2 - Clinical Cure News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical cure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Cure Today - Breaking & Trending Today

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2. ....

United States , Davidp Luci , Prnewswire Acurx Pharmaceuticals Inc , Company Scientific Advisory Board , Acurx Pharmaceuticals , European Medicines Agency , Exchange Commission On Form , Society Or Healthcare Epidemiology Of America , Drug Administration , Data Monitoring Committee , Infectious Diseases Society Of America , Acurx Pharmaceuticals Inc , Trial Oversight Committee , Company Ph , Briefing Document , Medium Sized Enterprise , New Drug Application , Meeting Request , Meeting Package , Scientific Advice , Marketing Authorizations , Executive Chairman , Marketing Authorization , Ibezapolstat Phase , Scientific Advisory Board , Clinical Cure ,

Acurx Pharmaceuticals (ACXP) Announces Positive Extended Clinical Cure Data for Ibezapolstat

Acurx Pharmaceuticals (ACXP) Announces Positive Extended Clinical Cure Data for Ibezapolstat
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Davidp Luci , Robertj Deluccia , Acurx Pharmaceuticals Inc , Acurx Pharmaceuticals , Clinical Cure , Executive Chairman , Extended Clinical Cure , Sustained Clinical Cure ,

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients

Acurx Pharmaceuticals, Inc. announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company s recently completed Phase 2b clinical. ....

United States , Company Scientific Advisory Board , Data Monitoring Committee , Acurx Pharmaceuticals Inc , Trial Oversight Committee , European Medicines Agency , Acurx Pharmaceuticals , First Quarter , Extended Clinical Cure , Scientific Advisory Board , Clinical Cure , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Fast Track Designated ,

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin. ....

United States , University Of Houston , Davidp Luci , Kevin Garey , Robertj Deluccia , Acurx Pharmaceuticals , Society Or Healthcare Epidemiology Of America , Company Ph , Company Scientific Advisory Board , Exchange Commission , Data Monitoring Committee , University Of Houston College Pharmacy , Trial Oversight Committee , European Medicines Agency , Drug Administration , Exchange Commission On Form , Acurx Pharmaceuticals Inc , Infectious Diseases Society Of America , Extended Clinical Cure , Gulf Coast Consortia Antimicrobial Resistance , Houston College , Principal Investigator , Acurx Scientific Advisory Board , Double Blind Study , Ibezapolstat Compared , Executive Chairman ,

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure at end of treatment remained free of C. difficile Infection recurrence through one month after EOT, for a Sustained. ....

United States , Kevin Garey , Stuart Johnson , Robertj Deluccia , Davidp Luci , Acurx Pharmaceuticals Inc , Infectious Diseases Society Of America , University Of Houston College Pharmacy , Data Monitoring Committee , Exchange Commission On Form , Drug Administration , Company Ph , Trial Oversight Committee , Society Or Healthcare Epidemiology Of America , Exchange Commission , Company Scientific Advisory Board , Loyola University Infectious Disease , European Medicines Agency , Acurx Pharmaceuticals , Prnewswire Acurx Pharmaceuticals Inc , Clinical Cure , Sustained Clinical Cure , Extended Clinical Cure , Houston College , Principal Investigator , Acurx Scientific Advisory Board ,